ProMIS Neurosciences Overview

  • Founded
  • 2004

Founded
  • Status
  • Public

  • Employees
  • 6

Employees
  • Stock Symbol
  • PMN

Stock Symbol
  • Investments
  • 2

  • Share Price
  • $5.38

  • (As of Tuesday Closing)

ProMIS Neurosciences General Information

Description

ProMIS Neurosciences Inc is focused on the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis, and multiple system atrophy. The company also plans to investigate additional synucleionapathies, including Parkinson's disease, and dementia with Lewy bodies. It primarily operates in Canada.

Contact Information

Formerly Known As
Amorfix Life Sciences
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
TSE
Primary Office
  • 1920 Yonge Street
  • Suite 200
  • Toronto, Ontario M4S 3E2
  • Canada

ProMIS Neurosciences Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ProMIS Neurosciences Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.38 $5.73 $4.38 - $9.44 $49.1M 8.58M 1.58K -$1.51

ProMIS Neurosciences Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 35,260 32,069 22,442 35,057
Revenue 8 8 1 1
EBITDA (12,204) (8,932) (4,208) (5,566)
Net Income (12,647) (9,395) (4,220) (5,572)
Total Assets 5,382 17,615 1,086 1,587
Total Debt 0 3,877 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ProMIS Neurosciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ProMIS Neurosciences‘s full profile, request access.

Request a free trial

ProMIS Neurosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
ProMIS Neurosciences Inc is focused on the discovery and development of precision medicine solutions for early detection
Drug Discovery
Toronto, Canada
6 As of 2021
000.00
000000000 000.00

000000

onsequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nul
0000 000000000
New York, NY
00 As of 0000
00.00
000000 - 000 00.00

0000

tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitat
0000000000000
San Diego, CA
00 As of 0000
00.000
0.00 0000-00-00
0000000000 0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ProMIS Neurosciences Competitors (31)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Anavex Life Sciences Corporation New York, NY 00 00.00 000000 - 000 00.00
0000 Venture Capital-Backed San Diego, CA 00 00.000 0000000000 0
00000000 000000000 Formerly VC-backed Boston, MA 0 00000 000000&0 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00.000 000000000 00.000
0000000 Venture Capital-Backed San Carlos, CA 00 000.00 00000000000 000.00
You’re viewing 5 of 31 competitors. Get the full list »

ProMIS Neurosciences Patents

ProMIS Neurosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021265165-A1 Single chain antibodies and intrabodies to misfolded tdp-43 and methods of use Pending 29-Apr-2020
US-20220218805-A1 Conformation-specific epitopes in tau, antibodies thereto and methods related thereof Pending 27-May-2019 00000000
JP-2022534406-A Conformation-specific epitopes of tau, antibodies against them, and related methods Pending 27-May-2019 00000000
AU-2020284288-A1 Conformation-specific epitopes in tau, antibodies thereto and methods related thereof Pending 27-May-2019 00000000000
CA-3142040-A1 Conformation-specific epitopes in tau, antibodies thereto and methods related thereof Pending 27-May-2019 A61K39/0005
To view ProMIS Neurosciences’s complete patent history, request access »

ProMIS Neurosciences Executive Team (11)

Name Title Board Seat Contact Info
Gail Farfel Ph.D Chief Executive Officer
Daniel Geffken Chief Financial Officer, Finance
Gavin Malenfant Chief Operating Officer, Operations
Neil Cashman Chief Scientific Officer & Board Member
David Wishart Chief Physics Officer
You’re viewing 5 of 11 executive team members. Get the full list »

ProMIS Neurosciences Board Members (8)

Name Representing Role Since
Eugene Williams ProMIS Neurosciences Chairman & Founder 000 0000
Maggie Shafmaster ProMIS Neurosciences Board Member 000 0000
Neil Cashman ProMIS Neurosciences Chief Scientific Officer & Board Member 000 0000
Neil Warma ProMIS Neurosciences Board Member 000 0000
Patrick Kirwin ProMIS Neurosciences Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

ProMIS Neurosciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ProMIS Neurosciences Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ProMIS Neurosciences‘s full profile, request access.

Request a free trial

ProMIS Neurosciences Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 00 09-Jul-2020 00000 0000 Diagnostic Equipment 000000 00
Amorfix Life Sciences 08-Jul-2015 Merger/Acquisition Therapeutic Devices
To view ProMIS Neurosciences’s complete investments and acquisitions history, request access »